AMLX Q1 2022 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$48M

Net Income

-$48M

EPS (Diluted)

$-0.93

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$274M

Total Liabilities

$33M

Stockholders' Equity

$241M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$48M	-$13M	-271.6%
Net Income	-$48M	-$15M	-229.5%